Skip to main content
Top
Published in: BMC Psychiatry 1/2019

Open Access 01-12-2019 | Schizophrenia | Research article

Severity in sustained attention impairment and clozapine-resistant schizophrenia: a retrospective study

Authors: An-Sheng Lin, Hung-Yu Chan, Ying-Chieh Peng, Wei J. Chen

Published in: BMC Psychiatry | Issue 1/2019

Login to get access

Abstract

Background

Among patients with treatment-resistant schizophrenia (TRS), some exhibited further clozapine resistance (CR). This study aimed to investigate whether greater severity of treatment resistance in schizophrenia is associated with greater impairments in sustained attention.

Methods

Patients with a DSM-IV-defined schizophrenia were recruited from a psychiatric center in northern Taiwan (April 2010 to October 2010). Both TRS and CR were determined retrospectively from participants’ medical records following the consensus guidelines. The patients were divided into three groups: 102 non-TRS, 48 TRS without CR, and 54 TRS with CR. They underwent both undegraded and degraded Continuous Performance Tests (CPT), and their performance scores (d′) were standardized against a community sample to derive age-, sex-, and education-adjusted z scores.

Results

The TRS with CR group had significantly lower adjusted z scores of d′ on both undegraded and degraded CPTs than the other two groups. Meanwhile, the differences between the TRS without CR group and the non-TRS group were not significant. Multivariable linear regression analyses with adjustment for covariates revealed a trend of gradient impairments on the degraded CPT from non-TRS to TRS without CR and to TRS with CR. The proportions of attentional deficits (an adjusted z score of ≤ − 2.5) on the degraded CPT also exhibited a significant trend, from 36.3% in the non-TRS group to 62.5% in the TRS without CR group and to 83.3% in the TRS with CR group.

Conclusions

Greater severity of treatment resistance in schizophrenia was associated with greater impairments in sustained attention, indicating some common vulnerability.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, American Psychiatric Association Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161:1–56. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, American Psychiatric Association Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161:1–56.
2.
go back to reference Elkis H. Treatment-resistant schizophrenia. Psychiatr Clin North Am. 2007;30:511–33.CrossRef Elkis H. Treatment-resistant schizophrenia. Psychiatr Clin North Am. 2007;30:511–33.CrossRef
3.
go back to reference Itil TM, Keskiner A, Fink M. Therapeutic studies in "therapy resistant" schizophrenic patients. Compr Psychiatry. 1966;7:488–93.CrossRef Itil TM, Keskiner A, Fink M. Therapeutic studies in "therapy resistant" schizophrenic patients. Compr Psychiatry. 1966;7:488–93.CrossRef
4.
go back to reference Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry. 2001;50:898–911.CrossRef Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry. 2001;50:898–911.CrossRef
5.
go back to reference Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, Bloomfield MA, Bressan RA, Buchanan RW, Carpenter WT, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174:216–29.CrossRef Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, Bloomfield MA, Bressan RA, Buchanan RW, Carpenter WT, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174:216–29.CrossRef
6.
go back to reference Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789–96.CrossRef Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789–96.CrossRef
7.
go back to reference Anderson VM, McIlwain ME, Kydd RR, Russell BR. Does cognitive impairment in treatment-resistant and ultra-treatment-resistant schizophrenia differ from that in treatment responders? Psychiatry Res. 2015;230:811–8.CrossRef Anderson VM, McIlwain ME, Kydd RR, Russell BR. Does cognitive impairment in treatment-resistant and ultra-treatment-resistant schizophrenia differ from that in treatment responders? Psychiatry Res. 2015;230:811–8.CrossRef
8.
go back to reference Elkis H, Buckley PF. Treatment-resistant schizophrenia. Psychiatr Clin North Am. 2016;39:239–65.CrossRef Elkis H, Buckley PF. Treatment-resistant schizophrenia. Psychiatr Clin North Am. 2016;39:239–65.CrossRef
9.
go back to reference Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987;44:660–9.CrossRef Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987;44:660–9.CrossRef
10.
go back to reference Murray RM, O'Callaghan E, Castle DJ, Lewis SW. A neurodevelopmental approach to the classification of schizophrenia. Schizophr Bull. 1992;18:319–32.CrossRef Murray RM, O'Callaghan E, Castle DJ, Lewis SW. A neurodevelopmental approach to the classification of schizophrenia. Schizophr Bull. 1992;18:319–32.CrossRef
11.
go back to reference Fatemi SH, Folsom TD. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull. 2009;35:528–48.CrossRef Fatemi SH, Folsom TD. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull. 2009;35:528–48.CrossRef
12.
go back to reference Rapoport JL, Giedd JN, Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. Mol Psychiatry. 2012;17:1228–38.CrossRef Rapoport JL, Giedd JN, Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. Mol Psychiatry. 2012;17:1228–38.CrossRef
13.
go back to reference Sheitman BB, Lieberman JA. The natural history and pathophysiology of treatment resistant schizophrenia. J Psychiatr Res. 1998;32:143–50.CrossRef Sheitman BB, Lieberman JA. The natural history and pathophysiology of treatment resistant schizophrenia. J Psychiatr Res. 1998;32:143–50.CrossRef
14.
go back to reference Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012;169:1203–10.CrossRef Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012;169:1203–10.CrossRef
15.
go back to reference Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, McGuire PK. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry. 2014;75:e11–3.CrossRef Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, McGuire PK. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry. 2014;75:e11–3.CrossRef
16.
go back to reference Goldstein ME, Anderson VM, Pillai A, Kydd RR, Russell BR. Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia. Int J Neuropsychopharmacol. 2015;18.CrossRef Goldstein ME, Anderson VM, Pillai A, Kydd RR, Russell BR. Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia. Int J Neuropsychopharmacol. 2015;18.CrossRef
17.
go back to reference Anderson VM, Goldstein ME, Kydd RR, Russell BR. Extensive gray matter volume reduction in treatment-resistant schizophrenia. Int J Neuropsychopharmacol. 2015;18:pyv016.CrossRef Anderson VM, Goldstein ME, Kydd RR, Russell BR. Extensive gray matter volume reduction in treatment-resistant schizophrenia. Int J Neuropsychopharmacol. 2015;18:pyv016.CrossRef
18.
go back to reference Gillespie AL, Samanaite R, Mill J, Egerton A, MacCabe JH. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review. BMC Psychiatry. 2017;17:12.CrossRef Gillespie AL, Samanaite R, Mill J, Egerton A, MacCabe JH. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review. BMC Psychiatry. 2017;17:12.CrossRef
19.
go back to reference Lin AS, Chang SS, Lin SH, Peng YC, Hwu HG, Chen WJ. Minor physical anomalies and craniofacial measures in patients with treatment-resistant schizophrenia. Psychol Med. 2015;45:1839–50.CrossRef Lin AS, Chang SS, Lin SH, Peng YC, Hwu HG, Chen WJ. Minor physical anomalies and craniofacial measures in patients with treatment-resistant schizophrenia. Psychol Med. 2015;45:1839–50.CrossRef
20.
go back to reference de Bartolomeis A, Prinzivalli E, Callovini G, D'Ambrosio L, Altavilla B, Avagliano C, Iasevoli F. Treatment resistant schizophrenia and neurological soft signs may converge on the same pathology: evidence from explanatory analysis on clinical, psychopathological, and cognitive variables. Prog Neuro-Psychopharmacol Biol Psychiatry. 2018;81:356–66.CrossRef de Bartolomeis A, Prinzivalli E, Callovini G, D'Ambrosio L, Altavilla B, Avagliano C, Iasevoli F. Treatment resistant schizophrenia and neurological soft signs may converge on the same pathology: evidence from explanatory analysis on clinical, psychopathological, and cognitive variables. Prog Neuro-Psychopharmacol Biol Psychiatry. 2018;81:356–66.CrossRef
21.
go back to reference Seidman LJ, Mirsky AF. Evolving notions of schizophrenia as a developmental neurocognitive disorder. J Int Neuropsychol Soc. 2017;23:881–92.CrossRef Seidman LJ, Mirsky AF. Evolving notions of schizophrenia as a developmental neurocognitive disorder. J Int Neuropsychol Soc. 2017;23:881–92.CrossRef
22.
go back to reference Green MF. Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia. J Clin Psychiatry. 2016;77(Suppl 2):8–11.CrossRef Green MF. Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia. J Clin Psychiatry. 2016;77(Suppl 2):8–11.CrossRef
23.
go back to reference Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003;160:636–45.CrossRef Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003;160:636–45.CrossRef
24.
go back to reference Beck LH, Bransome ED Jr, Mirsky AF, Rosvold HE, Sarason I. A continuous performance test of brain damage. J Consult Psychol. 1956;20:343–50.CrossRef Beck LH, Bransome ED Jr, Mirsky AF, Rosvold HE, Sarason I. A continuous performance test of brain damage. J Consult Psychol. 1956;20:343–50.CrossRef
25.
go back to reference Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, et al. The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165:203–13.CrossRef Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, et al. The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165:203–13.CrossRef
26.
go back to reference Chen WJ. Taiwan schizophrenia linkage study: lessons learned from endophenotype-based genome-wide linkage scans and perspective. Am J Med Genet B Neuropsychiatr Genet. 2013;162B:636–47.CrossRef Chen WJ. Taiwan schizophrenia linkage study: lessons learned from endophenotype-based genome-wide linkage scans and perspective. Am J Med Genet B Neuropsychiatr Genet. 2013;162B:636–47.CrossRef
27.
go back to reference Asarnow RF, MacCrimmon DJ. Span of apprehension deficits during the postpsychotic stages of schizophrenia. A replication and extension. Arch Gen Psychiatry. 1981;38:1006–11.CrossRef Asarnow RF, MacCrimmon DJ. Span of apprehension deficits during the postpsychotic stages of schizophrenia. A replication and extension. Arch Gen Psychiatry. 1981;38:1006–11.CrossRef
28.
go back to reference Nuechterlein KH, Dawson ME. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr Bull. 1984;10:160–203.CrossRef Nuechterlein KH, Dawson ME. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr Bull. 1984;10:160–203.CrossRef
29.
go back to reference Gur RE, Calkins ME, Gur RC, Horan WP, Nuechterlein KH, Seidman LJ, Stone WS. The consortium on the genetics of schizophrenia: neurocognitive endophenotypes. Schizophr Bull. 2007;33:49–68.CrossRef Gur RE, Calkins ME, Gur RC, Horan WP, Nuechterlein KH, Seidman LJ, Stone WS. The consortium on the genetics of schizophrenia: neurocognitive endophenotypes. Schizophr Bull. 2007;33:49–68.CrossRef
30.
go back to reference Liu SK, Chen WJ, Chang CJ, Lin HN. Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol. Neuropsychopharmacology. 2000;22:311–9.CrossRef Liu SK, Chen WJ, Chang CJ, Lin HN. Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol. Neuropsychopharmacology. 2000;22:311–9.CrossRef
31.
go back to reference Tsuang HC, Lin SH, Liu SK, Hsieh MH, Hwang TJ, Liu CM, Hwu HG, Chen WJ. More severe sustained attention deficits in nonpsychotic siblings of multiplex schizophrenia families than in those of simplex ones. Schizophr Res. 2006;87:172–80.CrossRef Tsuang HC, Lin SH, Liu SK, Hsieh MH, Hwang TJ, Liu CM, Hwu HG, Chen WJ. More severe sustained attention deficits in nonpsychotic siblings of multiplex schizophrenia families than in those of simplex ones. Schizophr Res. 2006;87:172–80.CrossRef
32.
go back to reference Lin SH, Liu CM, Hwang TJ, Hsieh MH, Hsiao PC, Faraone SV, Tsuang MT, Hwu HG, Chen WJ. Performance on the Wisconsin card sorting test in families of schizophrenia patients with different familial loadings. Schizophr Bull. 2013;39:537–46.CrossRef Lin SH, Liu CM, Hwang TJ, Hsieh MH, Hsiao PC, Faraone SV, Tsuang MT, Hwu HG, Chen WJ. Performance on the Wisconsin card sorting test in families of schizophrenia patients with different familial loadings. Schizophr Bull. 2013;39:537–46.CrossRef
33.
go back to reference Woodward N, Meltzer H. Neuropsychology of treatment-resistant schizophrenia. In: Elkis H, Meltzer H, editors. Therapy-resistant schizophrenia, vol. 26. Basel (Switzerland): Karger; 2010. p. 33–51.CrossRef Woodward N, Meltzer H. Neuropsychology of treatment-resistant schizophrenia. In: Elkis H, Meltzer H, editors. Therapy-resistant schizophrenia, vol. 26. Basel (Switzerland): Karger; 2010. p. 33–51.CrossRef
34.
go back to reference de Bartolomeis A, Balletta R, Giordano S, Buonaguro EF, Latte G, Iasevoli F. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses. Psychiatry Res. 2013;210:387–95.CrossRef de Bartolomeis A, Balletta R, Giordano S, Buonaguro EF, Latte G, Iasevoli F. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses. Psychiatry Res. 2013;210:387–95.CrossRef
35.
go back to reference Frydecka D, Beszlej JA, Goscimski P, Kiejna A, Misiak B. Profiling cognitive impairment in treatment-resistant schizophrenia patients. Psychiatry Res. 2016;235:133–8.CrossRef Frydecka D, Beszlej JA, Goscimski P, Kiejna A, Misiak B. Profiling cognitive impairment in treatment-resistant schizophrenia patients. Psychiatry Res. 2016;235:133–8.CrossRef
36.
go back to reference Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, Md.: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, Md.: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
37.
go back to reference Kane JM, Leucht S, Carpenter D, Docherty JP. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64:5–19.CrossRef Kane JM, Leucht S, Carpenter D, Docherty JP. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64:5–19.CrossRef
38.
go back to reference Chen WJ, Hsiao CK, Hsiao LL, Hwu HG. Performance of the continuous performance test among community samples. Schizophr Bull. 1998;24:163–74.CrossRef Chen WJ, Hsiao CK, Hsiao LL, Hwu HG. Performance of the continuous performance test among community samples. Schizophr Bull. 1998;24:163–74.CrossRef
39.
go back to reference Swets JA. The relative operating characteristic in psychology: a technique for isolating effects of response bias finds wide use in the study of perception and cognition. Science. 1973;182:990–1000.CrossRef Swets JA. The relative operating characteristic in psychology: a technique for isolating effects of response bias finds wide use in the study of perception and cognition. Science. 1973;182:990–1000.CrossRef
40.
go back to reference Nuechterlein KH. Vigilance in schizophrenia and related disorders. In: Steinhauer SR, Gruzelier JH, Zubin J, editors. Handbook of schizophrenia: neuropsychology, psychophysiology, and information processing, vol. 5. Amsterdam: Elsevier Science; 1991. p. 397–433. Nuechterlein KH. Vigilance in schizophrenia and related disorders. In: Steinhauer SR, Gruzelier JH, Zubin J, editors. Handbook of schizophrenia: neuropsychology, psychophysiology, and information processing, vol. 5. Amsterdam: Elsevier Science; 1991. p. 397–433.
41.
go back to reference Chen WJ, Liu SK, Chang CJ, Lien YJ, Chang YH, Hwu HG. Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients. Am J Psychiatry. 1998;155:1214–20.CrossRef Chen WJ, Liu SK, Chang CJ, Lien YJ, Chang YH, Hwu HG. Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients. Am J Psychiatry. 1998;155:1214–20.CrossRef
42.
go back to reference Chen WJ, Chang CH, Liu SK, Hwang TJ, Hwu HG. Sustained attention deficits in nonpsychotic relatives of schizophrenic patients: a recurrence risk ratio analysis. Biol Psychiatry. 2004;55:995–1000.CrossRef Chen WJ, Chang CH, Liu SK, Hwang TJ, Hwu HG. Sustained attention deficits in nonpsychotic relatives of schizophrenic patients: a recurrence risk ratio analysis. Biol Psychiatry. 2004;55:995–1000.CrossRef
43.
go back to reference Elliott AC, Reisch JS. Implementing a multiple comparison test for proportions in a 2xc crosstabulation in SAS®. Proceedings of the SAS User's Group International. 2006;31:204–31. Elliott AC, Reisch JS. Implementing a multiple comparison test for proportions in a 2xc crosstabulation in SAS®. Proceedings of the SAS User's Group International. 2006;31:204–31.
44.
go back to reference Iasevoli F, Balletta R, Gilardi V, Giordano S, de Bartolomeis A. Tobacco smoking in treatment-resistant schizophrenia patients is associated with impaired cognitive functioning, more severe negative symptoms, and poorer social adjustment. Neuropsychiatr Dis Treat. 2013;9:1113–20.CrossRef Iasevoli F, Balletta R, Gilardi V, Giordano S, de Bartolomeis A. Tobacco smoking in treatment-resistant schizophrenia patients is associated with impaired cognitive functioning, more severe negative symptoms, and poorer social adjustment. Neuropsychiatr Dis Treat. 2013;9:1113–20.CrossRef
45.
go back to reference Mackowick KM, Barr MS, Wing VC, Rabin RA, Ouellet-Plamondon C, George TP. Neurocognitive endophenotypes in schizophrenia: modulation by nicotinic receptor systems. Prog Neuro-Psychopharmacol Biol Psychiatry. 2014;52:79–85.CrossRef Mackowick KM, Barr MS, Wing VC, Rabin RA, Ouellet-Plamondon C, George TP. Neurocognitive endophenotypes in schizophrenia: modulation by nicotinic receptor systems. Prog Neuro-Psychopharmacol Biol Psychiatry. 2014;52:79–85.CrossRef
46.
go back to reference Nuechterlein KH, Parasuraman R, Jiang Q. Visual sustained attention: image degradation produces rapid sensitivity decrement over time. Science. 1983;220:327–9.CrossRef Nuechterlein KH, Parasuraman R, Jiang Q. Visual sustained attention: image degradation produces rapid sensitivity decrement over time. Science. 1983;220:327–9.CrossRef
47.
go back to reference Cornblatt BA, Lenzenweger MF, Erlenmeyer-Kimling L. The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients. Psychiatry Res. 1989;29:65–85.CrossRef Cornblatt BA, Lenzenweger MF, Erlenmeyer-Kimling L. The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients. Psychiatry Res. 1989;29:65–85.CrossRef
48.
go back to reference Nuechterlein KH, Green MF, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Radant AD, Seidman LJ, et al. Attention/vigilance in schizophrenia: performance results from a large multi-site study of the consortium on the genetics of schizophrenia (COGS). Schizophr Res. 2015;163:38–46.CrossRef Nuechterlein KH, Green MF, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Radant AD, Seidman LJ, et al. Attention/vigilance in schizophrenia: performance results from a large multi-site study of the consortium on the genetics of schizophrenia (COGS). Schizophr Res. 2015;163:38–46.CrossRef
49.
go back to reference Cornblatt BA, Risch NJ, Faris G, Friedman D, Erlenmeyer-Kimling L. The continuous performance test, identical pairs version (CPT-IP): I. new findings about sustained attention in normal families. Psychiatry Res. 1988;26:223–38.CrossRef Cornblatt BA, Risch NJ, Faris G, Friedman D, Erlenmeyer-Kimling L. The continuous performance test, identical pairs version (CPT-IP): I. new findings about sustained attention in normal families. Psychiatry Res. 1988;26:223–38.CrossRef
50.
go back to reference Kahn PV, Walker TM, Williams TS, Cornblatt BA, Mohs RC, Keefe RS. Standardizing the use of the continuous performance test in schizophrenia research: a validation study. Schizophr Res. 2012;142:153–8.CrossRef Kahn PV, Walker TM, Williams TS, Cornblatt BA, Mohs RC, Keefe RS. Standardizing the use of the continuous performance test in schizophrenia research: a validation study. Schizophr Res. 2012;142:153–8.CrossRef
51.
go back to reference Liu SK, Hsieh MH, Hwang TJ, Hwu HG, Liao SC, Lin SH, Chen WJ. Re-examining sustained attention deficits as vulnerability indicators for schizophrenia: stability in the long term course. J Psychiatr Res. 2006;40:613–21.CrossRef Liu SK, Hsieh MH, Hwang TJ, Hwu HG, Liao SC, Lin SH, Chen WJ. Re-examining sustained attention deficits as vulnerability indicators for schizophrenia: stability in the long term course. J Psychiatr Res. 2006;40:613–21.CrossRef
52.
go back to reference Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004;72:29–39.CrossRef Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004;72:29–39.CrossRef
53.
go back to reference Seidman LJ, Hellemann G, Nuechterlein KH, Greenwood TA, Braff DL, Cadenhead KS, Calkins ME, Freedman R, Gur RE, Gur RC, et al. Factor structure and heritability of endophenotypes in schizophrenia: findings from the consortium on the genetics of schizophrenia (COGS-1). Schizophr Res. 2015;163:73–9.CrossRef Seidman LJ, Hellemann G, Nuechterlein KH, Greenwood TA, Braff DL, Cadenhead KS, Calkins ME, Freedman R, Gur RE, Gur RC, et al. Factor structure and heritability of endophenotypes in schizophrenia: findings from the consortium on the genetics of schizophrenia (COGS-1). Schizophr Res. 2015;163:73–9.CrossRef
54.
go back to reference Frank J, Lang M, Witt SH, Strohmaier J, Rujescu D, Cichon S, Degenhardt F, Nothen MM, Collier DA, Ripke S, et al. Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients. Mol Psychiatry. 2015;20:150–1.CrossRef Frank J, Lang M, Witt SH, Strohmaier J, Rujescu D, Cichon S, Degenhardt F, Nothen MM, Collier DA, Ripke S, et al. Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients. Mol Psychiatry. 2015;20:150–1.CrossRef
55.
go back to reference Epstein JI, Keefe RSE, Roitman SL, Harvey PD, Mohs RC. Impact of neuroleptic medications on continuous performance test measures in schizophrenia. Biol Psychiatry. 1996;39:902–5.CrossRef Epstein JI, Keefe RSE, Roitman SL, Harvey PD, Mohs RC. Impact of neuroleptic medications on continuous performance test measures in schizophrenia. Biol Psychiatry. 1996;39:902–5.CrossRef
56.
go back to reference Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–76.CrossRef Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–76.CrossRef
57.
go back to reference Overall JE, Gorham DR. The brief psychiatric rating-scale. Psychol Rep. 1962;10:799–812.CrossRef Overall JE, Gorham DR. The brief psychiatric rating-scale. Psychol Rep. 1962;10:799–812.CrossRef
58.
go back to reference Brebion G, Bressan RA, Amador X, Malaspina D, Gorman JM. Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs. Psychol Med. 2004;34:369–74.CrossRef Brebion G, Bressan RA, Amador X, Malaspina D, Gorman JM. Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs. Psychol Med. 2004;34:369–74.CrossRef
Metadata
Title
Severity in sustained attention impairment and clozapine-resistant schizophrenia: a retrospective study
Authors
An-Sheng Lin
Hung-Yu Chan
Ying-Chieh Peng
Wei J. Chen
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2019
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-019-2204-6

Other articles of this Issue 1/2019

BMC Psychiatry 1/2019 Go to the issue